SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the third quarter 2026 and provided an update on the company’s recent developments.
“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,” said Thane Wettig, Chief Executive Officer of Kyntra Bio. “We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial. The unmet medical need and corresponding multi-billion-dollar commercial opportunity in LR-MDS is significant. Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027.”
Key Highlights of Third Quarter, Recent Developments, and Upcoming Milestones
Roxadustat
FG-3246 (CD46 Targeting ADC) and FG-3180 (CD46 Targeting PET Imaging Agent)
Corporate
Financial
Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.
About Roxadustat
Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin.
Roxadustat is approved in Europe, Japan, China, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Kyntra Bio has the sole rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas. Astellas and Kyntra Bio are collaborating on the commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa.
Following promising results from the Phase 2/3 MATTERHORN study, the Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB).
About Kyntra Bio
Kyntra Bio is a pure play, rare disease biopharmaceutical company focused on the development of roxadustat for anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). For more information, please visit www.kyntrabio.com.
Forward-Looking Statements
This release contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Kyntra Bio products and product candidates, statements under the caption “Recent Highlights and Upcoming Milestones”, statements about regulatory interactions, statements regarding cash, such as the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund Kyntra Bio’s operating plans into 2028, and statements about Kyntra Bio’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Kyntra Bio’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in Kyntra Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Kyntra Bio undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
Condensed Consolidated Balance Sheets
(In thousands)
| September 30, 2026 | December 31, 2025 | ||||||
| (Unaudited) | (1) | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 9,905 | $ | 47,872 | |||
| Short-term investments | 30,385 | 41,106 | |||||
| Accounts receivable, net | 3,848 | 216 | |||||
| Inventory | 3,255 | 3,743 | |||||
| Prepaid expenses and other current assets | 1,227 | 6,136 | |||||
| Total current assets | 48,620 | 99,073 | |||||
| Long-term investments | — | 20,160 | |||||
| Other assets | 231 | 361 | |||||
| Total assets | $ | 48,851 | $ | 119,594 | |||
| Liabilities, stockholders’ equity and non-controlling interests | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 4,581 | $ | 3,745 | |||
| Accrued and other liabilities | 31,005 | 20,183 | |||||
| Deferred revenue | 6,170 | 5,314 | |||||
| Total current liabilities | 41,756 | 29,242 | |||||
| Product development obligations | — | 19,560 | |||||
| Deferred revenue, net of current | 2,957 | 255 | |||||
| Liability related to sale of future revenues, non-current | 11,268 | 65,980 | |||||
| Other long-term liabilities | 60 | 82 | |||||
| Total liabilities | 56,041 | 115,119 | |||||
| Redeemable non-controlling interests | 21,480 | 21,480 | |||||
| Total stockholders’ deficit attributable to Kyntra Bio | (29,190 | ) | (30,038 | ) | |||
| Nonredeemable non-controlling interests | 520 | 13,033 | |||||
| Total deficit | (28,670 | ) | (17,005 | ) | |||
| Total liabilities, redeemable non-controlling interests and deficit | $ | 48,851 | $ | 119,594 | |||
(1) The condensed consolidated balance sheet amounts at December 31, 2025 are derived from audited financial statements.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| (Unaudited) | |||||||||||||||
| Revenue: | |||||||||||||||
| Development and other revenue | $ | 99 | $ | 119 | 449 | 396 | |||||||||
| Drug product revenue, net | 1,663 | 957 | 3,577 | 4,767 | |||||||||||
| Total revenue | 1,762 | 1,076 | 4,026 | 5,163 | |||||||||||
| Operating costs and expenses: | |||||||||||||||
| Cost of goods sold | 619 | (58 | ) | 4,727 | 278 | ||||||||||
| Research and development | 8,266 | 1,209 | 22,654 | 16,249 | |||||||||||
| Selling, general and administrative | 5,757 | 5,295 | 20,951 | 20,459 | |||||||||||
| Restructuring charge | (15 | ) | 41 | (48 | ) | 560 | |||||||||
| Total operating costs and expenses | 14,627 | 6,487 | 48,284 | 37,546 | |||||||||||
| Loss from operations | (12,865 | ) | (5,411 | ) | (44,258 | ) | (32,383 | ) | |||||||
| Interest and other, net: | |||||||||||||||
| Interest expense | (1,632 | ) | (2,083 | ) | (6,426 | ) | (6,346 | ) | |||||||
| Gain on deconsolidation of subsidiary | — | — | 30,940 | — | |||||||||||
| Loss on debt extinguishments | — | (6,583 | ) | — | (6,583 | ) | |||||||||
| Gain on debt restructuring | 14,011 | — | 14,011 | — | |||||||||||
| Interest income and other income (expenses), net | 643 | 931 | 2,731 | 1,628 | |||||||||||
| Total interest and other, net | 13,022 | (7,735 | ) | 41,256 | (11,301 | ) | |||||||||
| Income (loss) from continuing operations before income taxes | 157 | (13,146 | ) | (3,002 | ) | (43,684 | ) | ||||||||
| Benefit from income taxes | — | — | (1 | ) | (90 | ) | |||||||||
| Income (loss) from continuing operations | 157 | (13,146 | ) | (3,001 | ) | (43,594 | ) | ||||||||
| Income (loss) from discontinued operations, net of tax | — | 213,782 | (66 | ) | 241,266 | ||||||||||
| Net income (loss) | $ | 157 | $ | 200,636 | $ | (3,067 | ) | $ | 197,672 | ||||||
| Income (loss) from continuing operations per share - basic and diluted | $ | 0.04 | $ | (3.25 | ) | $ | (0.74 | ) | $ | (10.79 | ) | ||||
| Income (loss) from discontinued operations per share - basic and diluted | — | 52.86 | (0.02 | ) | 59.69 | ||||||||||
| Net income (loss) per share - basic and diluted | $ | 0.04 | $ | 49.61 | $ | (0.76 | ) | $ | 48.90 | ||||||
| Weighted average number of common shares used to calculate net income (loss) per share: | |||||||||||||||
| Basic | 4,049 | 4,044 | 4,048 | 4,042 | |||||||||||
| Diluted | 4,050 | 4,044 | 4,048 | 4,042 | |||||||||||
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com